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Matricellular proteins are secreted proteins that exist at the border of cells and the
extracellular matrix (ECM). However, instead of playing a role in structural integrity
of the ECM, these proteins, that act as modulators of various surface receptors,
have a regulatory function and instruct a multitude of cellular responses. Among
matricellular proteins are members of the Cyr61/CTGF/NOV (CCN) protein family.
These proteins exert their activity by binding directly to integrins and heparan sulfate
proteoglycans and activating multiple intracellular signaling pathways. CCN proteins
also influence the activity of growth factors and cytokines and integrate their activity
with integrin signaling. At the cellular level, CCN proteins regulate gene expression
and cell survival, proliferation, differentiation, senescence, adhesion, and migration.
To date, CCN proteins have been extensively studied in the context of osteo- and
chondrogenesis, angiogenesis, and carcinogenesis, but the expression of these proteins
is also observed in a variety of tissues. The role of CCN proteins in the nervous
system has not been systematically studied or described. Thus, the major aim of
this review is to introduce the CCN protein family to the neuroscience community.
We first discuss the structure, interactions, and cellular functions of CCN proteins
and then provide a detailed review of the available data on the neuronal expression
and contribution of CCN proteins to nervous system development, function, and
pathology.
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Introduction
Matricellular proteins are secreted proteins that exist at the border of cells and the extracellular
matrix (ECM). However, instead of playing a role in structural integrity of the ECM, these
proteins, that act as modulators of various surface receptors, have a regulatory function and
instruct a multitude of cellular responses. Thrombospondin-1 (TSP-1), SPARC, and Tenascin-C
(TN-C) are considered canonical matricellular proteins, however numerous new ones have been
described. Among them are members of the Cyr61/CTGF/NOV (CCN) protein family. Over the
last two decades neurobiologist have started to appreciate role of ECM in the nervous system
development, physiology and pathology. Accordingly, important contributions of canonical
matricellular proteins were described. In contrast, the CCN proteins, although expressed in the
nervous system, received relatively little attention in this context. Instead major research efforts
focused on their importance for cardiovascular system and skeleton development as well as
their links with cancer. Yet, over last few years evidence has accumulated that at least some of
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CCN family members play important role in the nervous
system, especially during development. Thus, the major aim
of this review is to introduce the CCN protein family
to the neuroscience community. We first briefly introduce
matricellular proteins in general. Next, we provide basic facts
about structure, interactions, and cellular functions of CCN
proteins that are needed as a background to understand the
involvement of these proteins in the nervous system. The
following parts of this article contain a detailed review of the
available data on the neuronal expression and contribution of
CCN proteins to nervous system development, function, and
pathology.
Matricellular Proteins
The idea of matricellular proteins arose almost 20 years
ago with the identification of pericellular matrix proteins,
which were shown to not be directly involved in structuring
the ECM but rather regulate cell function (Bornstein, 1995;
Bornstein and Sage, 2002; Murphy-Ullrich and Sage, 2014).
TSP-1, SPARC, and TN-C became prototypic matricellular
proteins, and their properties served as selection criteria for
the subsequent identification of other matricellular proteins
(Bornstein and Sage, 2002; Murphy-Ullrich and Sage, 2014).
Specifically, matricellular proteins should: (i) be highly expressed
during development or upon injury; (ii) modulate cell-matrix
interactions; (iii) bind to cell surface receptors, the ECM,
growth factors, cytokines, or proteases; and (iv) induce de-
adhesion or support states of ‘‘intermediate adhesion’’ (i.e.,
a condition characterized by the reorganization of F-actin
stress fibers to dismantle focal adhesions). Consequently, the
group of matricellular proteins expanded and now includes
additional TSPs (2–5), tenascins (R, W, X, Y), osteopontin,
and members of the CCN family (discussed in more detail
below; Murphy-Ullrich and Sage, 2014). The role of matricellular
proteins has been mostly studied in wound healing, cancer, and
the production of connective tissue. Some of these proteins,
however, have also been studied in the nervous system.
The classic matricellular proteins TSP-1 and SPARC were
shown to accelerate synaptogenesis when released by astrocytes
(Christopherson et al., 2005; Jones et al., 2011). Osteopontin
expression increases after ischemic or mechanical brain injury
and likely contributes to regenerative processes (Yan et al.,
2009; van Velthoven et al., 2011; Plantman, 2012). The use
of TN-C knockout mice revealed that TN-C is important for
neuromuscular junction formation and plasticity (Cifuentes-
Diaz et al., 1998), hippocampus and cortex structure and
electrical properties (Irintchev et al., 2005; Gurevicius et al.,
2009), hippocampal and cerebellar plasticity (Evers et al.,
2002; Andjus et al., 2005), olfactory detection (de Chevigny
et al., 2006) and learning and memory (Strekalova et al.,
2002). TN-C also positively regulates neurite outgrowth (Rigato
et al., 2002; Michele and Faissner, 2009). Similarly, TN-R
was shown to regulate multiple processes in the nervous
system, including neurogenesis (Xu et al., 2014), neuronal
migration (Saghatelyan et al., 2004), axon navigation and
neurite growth (Becker et al., 2003, 2004; Zacharias and
Rauch, 2006), the formation of perineuronal nets (Brückner
et al., 2000; Morawski et al., 2014), and neuron excitability
and plasticity (Saghatelyan et al., 2001; Nikonenko et al.,
2003; Gurevicius et al., 2004). In contrast, the CCN protein
family received relatively little attention from neurobiologists.
Nonetheless, CCN matricellular proteins are expressed in the
nervous system and some examples exist to confirm their
importance for the proper development and function of the
nervous system.
CCN Family
The CCN gene family (Cyr61/CTGF/NOV) consists of six
members: CCN-1 (Cyr61), CCN-2 (CTGF), CCN-3 (NOV), CCN-
4 (WISP1), CCN-5 (WISP2), and CCN-6 (WISP3). The family
name was derived from early nomenclature for the first three
identified proteins. These names often reflect the history of the
discovery of particular CCN proteins or an initial view of their
functions but may not necessarily reflect the current state of
knowledge. For example, CCN1 (Cyr61) was identified as 61st
gene among genes, the expression of which was induced by
trophic factors, e.g., epidermal growth factor (EGF) in fibroblasts
(Lau and Nathans, 1987). Because of its mitogenic activity in
connective tissue, CCN2 was named connective tissue growth
factor (CTGF; Bradham et al., 1991). CCN3 was cloned as
a gene that is overexpressed in nephroblastoma because of
proviral insertion sites, and it was consequently named after this
observation, i.e., Nephroblastoma overexpressed (NOV ; Joliot
et al., 1992). CCN4 and CCN5, initially called expressed in low-
metastatic type 1 cells (ELM-1; Hashimoto et al., 1998) and
card-only protein 1 (rCOP-1; Zhang et al., 1998), respectively,
were later identified as genes that were upregulated in response
to Wnt-1 and consequently renamed WNT-inducible signaling
pathway protein 1 (WISP1) and WISP2 (Pennica et al., 1998).
Finally, CCN6 was identified as a WISP1 homolog and named
WISP3. This diversity of names within the CCN gene family
(Table 1) became a major source of confusion and difficulty
in attempts to follow research progress in the CCN field.
Therefore, after the first international workshop on the CCN
Family of genes, CCN researchers proposed a unification of the
nomenclature for CCN family members (Brigstock et al., 2003);
see also http://ccnsociety.com/ccn_nomenclature/index.html),
which will be used hereinafter in the present review (Table 1).
CCN family genes encode relatively small proteins (∼40 kDa)
that share ∼40–60% similarity in their primary structure.
Their most prominent common features are their functional
domain composition and conservation of 38 cysteins through
the peptide (Figure 1). Consequently, CCN proteins have several
similarities in their molecular mechanisms of action and types
of regulated cellular processes (e.g., cell adhesion, migration,
proliferation, survival, and differentiation). However, the activity
of particular CCN members may vary, depending on the
cellular/tissue context (see below). Several extensive reviews have
been published on the molecular biology of CCN proteins and
their function in physiology and pathology (Leask and Abraham,
2006; Holbourn et al., 2008; Chen and Lau, 2009; Katsube et al.,
2009; Jun and Lau, 2011; Perbal, 2013).
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TABLE 1 | Alternative names and receptors of CCN proteins.
CCN1
Alternative names: Cyr611, CTGF-2, IGFB10, IGFB-rP4
Receptors: α6β12, αVβ3, αMβ2, α2β1, αVβ5, αDβ2, α2bβ3, HSPG
CCN2
Alternative names: CTFG, IGFBP8, IGFBP-rP2, HBGF0.8, ecogenin, FISP12
Receptors: αVβ3, α6β1, α5β1, αMβ2, TrkA, p75NTR, HPSG, LRP-1, LRP-6
CCN3
Alternative names: NOV, NOVH, IGFBP9, IGFBP-rP3
Receptors: αVβ3, α6β1, α5β1, αvβ5, Notch
CCN4
Alternative names: Wisp-1, Elm-1
Receptors: αvβ5 (Hou et al., 2013; Stephens et al., 2015); αVβ3
or β1 (Stephens et al., 2015), α5β1 (Liu et al., 2013)
CCN5
Alternative names: Wisp-2, CTGF-L, CTGF-3, HICP, Cop-1
Receptors: β1 integrin (Ohkawa et al., 2011), αvβ3 (Myers et al., 2014),
α6β1 (Haque et al., 2015)
CCN6
Alternative names: Wisp-3
Receptors: β1 integrin (Batmunkh et al., 2011), αυβ5 (Schütze et al., 2007)
Abbreviations: 1Cyr61 cystein rich 61, CTGF—connective tissue growth
factor, IGFB IGFB-rb—IGFB-related protein, HBGF—heparin-binding growth
factor, FISP12 fibroblast-inducible secreted protein, NOV—nephroblastoma
overexpressed, Wisp—Wnt-inducible secreted protein, Elm-1 expressed in low
metastatic cells, HICP—heparin-induced CCN-like protein, Cop-1 card only
protein 1. 2 if not stated otherwise please refer to Jun and Lau (2011) for more
detailed information.
Structure, Molecular Interactions, and Basic
Modes of Action of CCN Proteins
CCN proteins are structurally very similar. With the exception
of CCN5, CCNs contain four functional domains that
are preceded by an export signaling peptide at their N-
terminus, namely insulin-like growth factor binding protein
(IGFBP), a von Willebrand factor type C repeat (VWC),
thrombospondin type-1 repeat (TSP-1 or TSR), and a cystein
knot-containing domain (CT; Figure 1). The last of these
FIGURE 1 | Domain structure and canonical interactions of CCN family
members.
is missing in CCN5. IGFBP and VWC constitute the N-
terminal half of CCN proteins, which is separated from the
C-terminal half that contains TSP-1 and CT by a ‘‘hinge’’
region. Additional forms of CCNs, which have different
activities from full-length proteins, can be produced by
proteolysis (Brigstock et al., 1997; Steffen et al., 1998) or
alternative splicing (Perbal, 2009). Each of the CCN protein
domains is responsible for interactions with different sets of
molecules (Figure 1). Consequently, CCN proteins bridge
a variety of cell surface receptors, signaling molecules, and
the ECM. Thus, modular composition, which is unique for
the CCN family, explains the functional distinctiveness of
CCNs from other proteins that contain one of the domains
but raises the issue of what makes them functionally different
from each other. Three-dimensional structure modeling
revealed subtle changes in electrostatic surfaces that might
be responsible for the differential interactions of particular
CCN family members (Holbourn et al., 2008). However,
most experimental evidence points to other sources of
diversity, namely differential, often non-overlapping CCN
expression patterns and different sets of receptors and/or
proteins that interact with CCNs and are expressed by target
cells.
CCN proteins have two major modes of action: (i)
interactions with cell surface receptors; and (ii) interactions
with receptor ligands. To date, the best studied are the
cellular effects of CCN protein interactions with cell adhesion
receptors [i.e., integrins and heparan sulfate proteoglycans
(HSPGs); Table 1]. At the molecular level, such binding
results in the cellular context-specific activation of signaling
cascades, including extracellular signal-regulated kinases (ERKs),
phosphoinositide 3-kinase (PI3K), and small GTPases of the Rho
family (Leask and Abraham, 2006; Chen and Lau, 2009; Jun and
Lau, 2011). This in turn leads to myriad cellular responses, of
which changes in gene expression and cytoskeleton dynamics
have been the most extensively studied. Some non-canonical
outcomes (e.g., sustained reactive oxygen species production and
cell senescence in response to CCN1-induced Rac1 activation)
have also been described (Chen et al., 2007). One of the
characteristic futures of CCN members is an ability to interact
with various integrins (Table 1). Specific CCN proteins can bind
different integrins, triggering dissimilar cellular responses. For
example, in fibroblasts, CCN1 interactions with α6β1 stimulate
cell adhesion, whereas its binding to αvβ3 results in the induction
of DNA synthesis. Moreover, the binding sites for different β-
integrins do not overlap; therefore, simultaneous interactions
with two integrins and a combined outcome are possible.
However, cellular responses even to the same CCN protein-
integrin couple may vary depending on the cell type (see
below).
Integrins and HSPGs are currently the best described CCN
receptors, but they are not the only ones. For example,
the adhesion of rat hepatic stellate cells to a CCN2-coated
surface requires binding to low-density lipoprotein receptor-
related protein 1 (LRP-1) and HSPG (Gao and Brigstock,
2003). Binding to LRP-6 is likely responsible for the inhibitory
effects of CCN2 on the canonical Wnt pathway in developing
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Xenopus laevis embryos. CCN2 binds tyrosine kinase receptor-
A (TrkA) and p75 neurotrophin receptor (p75NTR; Wahab
et al., 2005), whereas Notch is a receptor for CCN3 (Sakamoto
et al., 2002; Minamizato et al., 2007). In addition to receptor
binding, CCNs interact with receptor ligands and modulate
their binding affinity or bioavailability. In the former case, the
most thoroughly described interactions include those between
CCNs and bone morphogenetic proteins (BMPs), which has an
inhibitory effect, and between CCNs and transforming growth
factor β (TGFβ), which has an activational effect (Abreu et al.,
2002). CCN2 and CCN1 bind vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor (bFGF),
respectively, and modify their bioavailability (Chen and Lau,
2009).
General Functions of CCN Proteins
Detailed descriptions of the functions of CCN proteins have
been provided in several reviews (Leask and Abraham, 2006;
Holbourn et al., 2008; Chen and Lau, 2009; Katsube et al.,
2009; Jun and Lau, 2011; Perbal, 2013). The diversity of CCNs’
modes of action results in a variety of cellular responses
to CCN proteins. CCNs have been shown to regulate often
converse cellular processes (e.g., cell proliferation/differentiation,
cell death/survival, and cell adhesion/migration; for review see
Jun and Lau, 2011; Table 2). Unsurprising is that different
CCNs regulate opposite cellular processes. For example, CCN1,
CCN2, and CCN3 are considered positive regulators of
adhesion, whereas CCN5 and CCN6 are considered negative
regulators (for review see Jun and Lau, 2011). However,
opposing or very diverse cellular responses to the same
CCN protein have also been reported. For example, CCN1
binds α6β1, αVβ3, α2Bβ3, and αMβ3 integrins and positively
regulates the adhesion of fibroblasts and smooth muscle
cells, activated endothelial cells, platelets, and monocytes
and macrophages, respectively (for review see Jun and Lau,
2011). However, the binding of CCN1 to αVβ5 and α6β1
induces the migration of fibroblasts and smooth muscle
cell chemotaxis, respectively (for review see Jun and Lau,
2011). As mentioned above, the binding of CCN1 to αvβ3
integrin in fibroblasts does not affect adhesion/migration
but rather regulates DNA synthesis. This example shows
that CCN1 can have pleiotropic activities, depending on the
cell type, functional/developmental cell status, and type of
accessible receptors (e.g., integrins). The same is true for
other CCN proteins (for review see Jun and Lau, 2011;
Table 2).
In addition to the intrinsic properties of a cell, the
surrounding environment/tissue can also modulate responses
to a particular CCN. Therefore, a deeper understanding of
the physiological roles of CCNs and their links to human
diseases became possible only with in vivo models. These in
vivo studies point to a primary role for CCN family members
in angiogenesis and cardiovascular and skeletal development.
For example, CCN1, CCN2, and CCN3 stimulate in vivo
blood vessel growth, whereas CCN1 knockout (CCN1−/−)
embryos die from placental vascular deficiency (Mo et al.,
2002). The surviving embryos exhibit atrioventricular septal
TABLE 2 | Cellular functions of CCN proteins.
CCN1
Cell adhesion1 (+)2, cell migration (+), DNA synthesis/proliferation (+), survival (+),
apoptosis (+), differentiation (+), senescence (+)
CCN2
Cell adhesion (+), cell migration (+), survival (+), apoptosis (+)
CCN3
Cell adhesion (+), cell migration (+/−), DNA synthesis/proliferation (−/+), survival
(+), apoptosis (+)
CCN4
Cell adhesion (+), (Liu et al., 2013; Stephens et al., 2015), migration (+) (Liu
et al., 2013), proliferation (+) (Liu et al., 2013), survival (+) (Hou et al., 2013;
Schlegelmilch et al., 2014)
CCN5
Cell migration (−), DNA synthesis/proliferation (−) (Haque et al., 2015), survival
(+) (Ohkawa et al., 2011)
CCN6
Proliferation (+) (Batmunkh et al., 2011; Fang et al., 2014), migration (+) (Fong
et al., 2012; Fang et al., 2014), survival (Huang et al., 2010)
1 if not stated otherwise please refer to Jun and Lau (2011) for more detailed
information. 2+ positive effect, −negative effect, −/+ either positive or negative
effect depending on cellular context.
defects. CCN1+/− mice are viable, but 20% of the adult
mice have ostium primum atrial septal defects (Mo and Lau,
2006). Also CCN2-deficient mice have defects in vasculature
remodeling (Hall-Glenn et al., 2012). CCN2, CCN3, CCN4,
and CCN6 are mostly known for their importance in bone
formation and/or remodeling. CCN2 knockout mice exhibit
skeletal deformations, reduced ossification, and the expansion
of mineralizing cartilage zones. In CCN3 knockout mice,
Matsushita et al. (2013) observed accelerated bone regeneration.
A study of transgenic mice that overexpress CCN4 in
preosteoblasts reported that CCN4 stimulates osteogenesis (Ono
et al., 2011). Finally, mutations in CCN6 were repeatedly
found in progressive pseudorheumatoid dysplasia, an autosomal
recessive disorder (Hurvitz et al., 1999). Surprisingly, however,
CCN6 knockout mice have no obvious bone phenotype
(Kutz et al., 2005; Hann et al., 2013), whereas some defects
that may be relevant to human disease were observed in
zebrafish morphants (Nakamura et al., 2007). In addition to
the major research areas described above, CCNs have been
extensively studied in the context of proper wound healing
(Jun and Lau, 2011). Mounting evidence also indicates links
between CCNs and tumorigenesis (Jun and Lau, 2011). In
contrast, knowledge concerning the role of CCNs in the
nervous system is relatively lagging. Part of the problem
is that full, nonconditional knockout results in embryonic
(CCN1, CCN5) or perinatal (CCN2) death. Often such early
lethality precludes studies on several tissue/organ functions,
including in the nervous system. In cases of CCN knockout
animals that survive embryonic development, no apparent
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nervous system problems were reported, but usually deeper
analyses in this regard have not been performed because
different authors have different major interests (e.g., bone
development). Another reason for the low recognition of
CCNs’ roles in the nervous system stems from scattering of
relevant information. To date, a comprehensive summary of
the current state of knowledge concerning CCN expression
patterns, the involvement of CCNs in neuronal development and
physiology, and their links to nervous system pathology has been
lacking.
Expression and Functions of CCN Family
Members in the Nervous System
Major research on CCN proteins has not focused on the
nervous system, but for some CCNs, the central nervous
system (CNS) is one of the major sites of expression. This
observation supports the hypothesis of a possible role for the
CNN protein family in different aspects of CNS physiology
and pathology. In fact, the role of some CNN family
members in the CNS has already been demonstrated, and the
number of reports concerning this issue is constantly growing.
CCN Expression in the Mammalian Central
Nervous System
CCN proteins are expressed in non-neuronal tissues
mainly during highly dynamic processes that involve tissue
remodeling. CCN expression is thus observed during
embryonic development and under pathological conditions
(e.g., inflammation, injury, and cancer). Similarly, in the
CNS, the expression of CCNs can be induced under such
conditions. For example, both CCN1 and CCN2 were elevated
in gliomas and glioblastomas (Pan et al., 2002; Xie et al.,
2004a,b). However, CCN proteins are also expressed in the
properly developing and adult CNS. Although knowledge of
the pattern of CCN expression during embryogenesis and
postnatal development and in the adult CNS is incomplete
and restricted mainly to CCN1, CCN2, and CCN3, the
number of studies that are investigating this issue is growing.
Additional information concerning CCN expression patterns
in the rodent and human brain can be extracted from large
databases, including the collection of Allen Brain Atlases
(ABA), e.g., Allen Mouse Brain Atlas (Lein et al., 2007)1
and Allen Developing Mouse Brain Atlas2 for in situ
hybridization data, BrainStars* (BS*) for microarray data
(Kasukawa et al., 2011)3, and the Human Protein Atlas (HPA)
for immunohistochemistry data (Uhlén et al., 2015).4 The
major advantages of these databases, which resulted from
large-scale projects, are standardized procedures, reagents,
and biological material. In this review, we use this knowledge
to discuss previously published data and identify gaps in the
literature.
1http://www.brain-map.org
2http://developingmouse.brain-map.org
3http://www.brainstars.org
4http://www.proteinatlas.org
CCN1 Expression in the Developing and Adult
Central Nervous System
CCN1 mRNA has been detected in different areas of the
developing and adult human and rat brain and in rat
hippocampal and cortical neurons cultured in vitro (Albrecht
et al., 2000; Malik et al., 2013). Interestingly, CCN1 mRNA
levels in the rat hippocampus were higher during embryonic
development and dropped postnatally, suggesting that this
protein may play an important role during embryonic brain
development (Malik et al., 2013). A similar developmental trend
in CCN1 expression was observed in cultured hippocampal
neurons (Malik et al., 2013). An analysis of ABA data showed
fluctuations of CCN1 mRNA amount in embryonic brain but
confirmed higher CCN1 mRNA levels in the mouse embryonic
day 18 (E18) brain compared with early postnatal weeks. The
ABA suggests partial expression recovery in the cortex from
postnatal day 28 (P28) onward (Figure 2). In the adult brain
(P56) the ABA provides evidence for CCN1 mRNA in deeper
cortical layers (Figure 3). BrainStars∗ provides evidence of CCN1
mRNA in the adult mouse CNS, with the highest levels in the
retina. In the adult human brain, CCN1 mRNA was detected
throughout the CNS, with the strongest expression in the spinal
cord, frontal, temporal, and occipital cortices, hippocampus,
and caudate nucleus (Albrecht et al., 2000). This observation
appears to be confirmed by the HPA, in which mild CCN1
protein levels were present in the cortex and hippocampus, but
the highest levels were detected in the cerebellum (Figure 4).
An analysis of the cell specificity of immunohistochemical
signal showed that CCN1 protein can be detected mostly in
neurons, whereas its expression in glia is lower or undetectable
(Table 3).
Our data from in vitro hippocampal neuron cultures showed
that CCN1 expression can be modulated by various stimuli
[e.g., brain-derived neurotrophic factor (BDNF), insulin, and
bicuculline], both in developing and ‘‘mature’’ neurons. The
effects of bicuculline suggest a role for enhanced excitatory
transmission in the regulation of CCN1 mRNA levels. Similar
results were obtained in organotypic hippocampal slices
(Iacono et al., 2013). In vivo, CCN1 mRNA level increases
with decreases in excitatory transmission that are caused by
N-methyl-D-aspartate receptor inhibition (Ito et al., 2007).
Nevertheless, the mechanism behind this phenomenon might
be indirect and involve increases in the activation of other
neurotransmitter systems. Elevations of CCN1 mRNA were
also observed upon methamphetamine administration (Ito
et al., 2007), administration of the dopamine receptor agonist
clozapine (Sakuma et al., 2015), and the activation of muscarinic
acetylcholine receptors (Chung and Ahn, 1998; Albrecht et al.,
2000).
CCN2 Expression in the Developing and Adult
Central Nervous System
Similar to CCN1, CCN2 is also expressed in different parts of
the CNS and rat primary neuron cultures in vitro (Albrecht
et al., 2000), and its levels are regulated developmentally. CCN2
mRNA is present in neural tissue in developing mouse embryos
already at embryonic day 9.5 (Ivkovic et al., 2003). Williams
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FIGURE 2 | Expression of CCN1–4 genes in the developing mouse
brain according to the Allen Developing Mouse Brain Atlas [© 2013
Allen Institute for Brain Science. Allen Developing Mouse Brain Atlas
(Internet)]. Gene expression summary for selected brain structures were
downloaded from http://developingmouse.brain-map.org/ and are expressed
as a heatmap of expression energy (for more details please refer to
http://help.brain-map.org/display/devmouse/In+Situ+Hybridization+
(ISH)+Data#InSituHybridization(ISH)Data-CorrelationSearch). Heatmaps
source: CCN1: http://developingmouse.brain-map.org/gene/show/15780;
CCN2: http://developingmouse.brain-map.org/gene/show/13996; CCN3:
http://developingmouse.brain-map.org/gene/show/17900; CCN4:
http://developingmouse.brain-map.org/gene/show/22159. RSP—rostral
secondary prosencephalon; Tel—telencephalic vesicle; PedHy—peduncular
(caudal) hypothalamus; p3 prosomere 3; p2 prosomere 2; p1 prosomere 1;
M—midbrain; PPH—prepontine hindbrain; PH—pontine hindbrain;
PMH—pontomedullary hindbrain; MH—medullary hindbrain (medulla).
et al. (2007) reported presence of CCN2 mRNA in olfactory
bulb at embryonic days 14, 17.5 and at postnatal day 3. In
the adult brain presence of both CCN2 mRNA and CCN2
protein was reported in the hippocampus (Hertel et al., 2000)
and olfactory bulb (Williams et al., 2007). The ABA shows
moderate levels of CCN2 mRNA between E11.5-E15.5 and a
complete lack of CCN2 expression just before birth. However,
CCN2 mRNA levels gradually increase from P4 until adulthood
(Figure 2). Such dynamic regulation of CCN2 expression in
early postnatal development was studied in detail in the rodent
olfactory bulb. CCN2 mRNA in the glomerular and mitral
cell layers could be detected around P5. In the glomerular
layer, CCN2 mRNA level remained stable throughout postnatal
development and in the adult brain, whereas it gradually
decreased in the mitral cell layer and was barely detectable
already on P12 (Khodosevich et al., 2013). In the adult rat brain,
CCN2 mRNA showed a highly selective distribution pattern
in the forebrain, with strong labeling that was restricted to
specific regions of the olfactory bulb, endopiriform nucleus, and
supracallosal layer in the cerebral cortex. Particularly strong
staining was observed in large neurons of layer VI in the
cerebral cortex (Heuer et al., 2003). In the adult mouse brain,
CCN2 mRNA could be detected in layer VI of the cortex
and mitral cell and glomerular layers of the olfactory bulb
(Khodosevich et al., 2013). These observations are consistent
with the ABA (Figure 3) and BS* data. Presence of CCN2
mRNA was also shown throughout the adult human CNS,
including different brain regions and the spinal cord. In fact,
the CCN2 expression pattern is similar to CCN1, with the
exception that tissue levels of CCN2 transcripts were lower
in the hippocampus, caudate nucleus, and corpus callosum
(Albrecht et al., 2000). In the healthy human brain, CCN2
protein was predominantly detected in neurons and partially
in subtypes of glial cells (Schwab et al., 2000, 2001; Table 3).
The HPA also suggests the presence of CCN2 protein in glial
cells, especially in cortical areas (Table 3). Supporting further
glial expression of CCN2, its expression has been detected in
rat CNS astrocytes and tanycytes (Kondo et al., 1999). In the
normal human spinal cord, the low expression of CCN2 was
observed in cells with astroglial morphology, particularly in
white matter (Spliet et al., 2003). In the senile human brain,
exclusively CCN2 neuronal expression was found throughout
different brain areas, particularly in entorhinal layer pre-alpha
neurons and cortical pyramidal cells, both in somatodendritic
and axonal compartments (Ueberham et al., 2003). Expression
of CCN2 also appears to be regulated by neuronal activity.
Khodosevich et al. (2013) demonstrated that CCN2 protein level
is dynamically regulated in response to changes in olfactory
input.
CCN3 Expression in the Developing and Adult
Central Nervous System
CCN3 is also expressed in the developing and adult CNS.
In fact, the CNS appears to be the major site of CCN3
expression during development compared with other tissues.
This was demonstrated in chick embryos (Joliot et al., 1992)
and human embryos in the first trimester of embryogenesis,
in which CCN3 mRNA and CCN3 were most abundantly
present in motor neurons and the floor plate of the spinal
cord (Kocialkowski et al., 2001). CCN3 expression undergoes
dynamic changes during development, suggesting that CCN3
protein might play a role in maintaining or establishing
specific brain functions. The abundance of CCN3 mRNA
increases throughout the postnatal period during rat brain
development. Increases in amount of CCN3 mRNA and CCN3
protein were detected in the developing rat brain after birth,
with a pronounced peak between P15 and P150 (Su et al.,
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 June 2015 | Volume 9 | Article 237
Malik et al. CCN proteins and the nervous system
FIGURE 3 | Expression of CCN1–5 genes in the adult mouse brain according to the Allen Brain Atlas [© 2014 Allen Institute for Brain Science. Allen
Mouse Brain Atlas (Internet)]. Images of brain sections were downloaded from http://mouse.brain-map.org/. Experiment name is given in parentheses.
2001). A similar increase seems to occur in the developing
murine brain according to the ABA (Figure 2) through a
majority of brain areas and the highest levels of CCN3
mRNA are present in olfactory bulb, cortex and CA1 field of
hippocampus (Figure 3). Intriguingly, the ABA also reports
relatively low levels of CCN3 mRNA in the cerebellum. But
CCN3 mRNA and CCN3 protein were detected in the rat
cerebellum during the postnatal period, with the most prominent
increase from P7 to P14 (Le Dréau et al., 2010b). In the
human brain during early developmental stages, CCN3 mRNA
was mainly observed in somatomotor neurons in the lower
CNS. At later stages, however, CCN3 was expressed in the
higher CNS (Su et al., 1998). High levels of CCN3 mRNA
were reported in the cortex, hippocampus, amygdala, and
spinal cord (Albrecht et al., 2000). Surprisingly, the HPA
reveals no CCN3 protein expression in the analyzed areas
(Figure 4).
CCN3 expression is particularly observed in neurons. For
example, presence of CCN3 mRNA was shown in rat neuronal
cultures in vitro (Albrecht et al., 2000) while CCN3 protein
was detected in rat cerebellar Purkinje cells (Su et al.,
2001; Le Dréau et al., 2010b), and neurons of dorsal root
ganglia and the dorsal horn of the rat spinal cord (Kular
FIGURE 4 | CCN protein abundance in the selected human brain
regions according to the Human Protein Atlas (HPA).
et al., 2012). However, CCN3 immunoreactivity was also
observed in astrocytes in the rat cerebral cortex, corpus
callosum, and hippocampus (Le Dréau et al., 2010a). CCN3
mRNA and CCN3 protein are also expressed in specific
structures in the developing chicken eye, including the lens,
ciliary body, optic nerve, pecten, and retina (Laurent et al.,
2012).
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TABLE 3 | Cellular specificity of CCN protein expression in selected regions of the CNS according to the Human Protein Atlas.
Cerebral cortex Hippocampus Lateral ventricle Cerebellum
CCN1 endothelial cells—medium
glial cells—low
neuronal cells—medium
neuropil—medium
glial cells—not detected
neuronal cells—medium
glial cells—low
neuronal cells—medium
cells in granular layer—medium
cells in molecular layer—low
Purkinje cells—high
CCN2 endothelial cells—medium
glial cells—medium
neuronal cells—medium
neuropil—medium
glial cells—low
neuronal cells—medium
glial cells—low
neuronal cells—medium
cells in granular layer—medium
cells in molecular layer—medium
Purkinje cells—medium
CCN3 endothelial cells—not detected
glial cells—not detected
neuronal cells—not detected
neuropil—not detected
glial cells—not detected
neuronal cells—not detected
glial cells—not detected
neuronal cells—not detected
cells in granular layer—not detected
cells in molecular layer—not detected
Purkinje cells—not detected
CCN4 endothelial cells—high
glial cells—medium
neuronal cells—medium
neuropil—medium
glial cells—medium
neuronal cells—medium
glial cells—medium
neuronal cells—medium
cells in granular layer—medium
cells in molecular layer—medium
Purkinje cells—high
CCN5 endothelial cells—not detected
glial cells—not detected
neuronal cells—medium
neuropil—not detected
glial cells—not detected
neuronal cells—medium
glial cells—not detected
neuronal cells—not detected
cells in granular layer—not detected
cells in molecular layer—not detected
Purkinje cells—not detected
CCN6 not analyzed not analyzed not analyzed not analyzed
CCN4, CCN5, and CCN6 Expression in the Central
Nervous System
In contrast to CCN1–3, very little is known about CCN4, CCN5,
and CCN6 expression patterns. The data that are available are
also somewhat contradictory. A study of CCN4, CCN5, and
CCN6 mRNA levels in human embryonic and adult tissues
showed no expression in the brain (Pennica et al., 1998), but
other studies do not fully support this finding. Indeed, during rat
embryonic development, CCN4 mRNA presence was reported
exclusively in osteoblasts and osteoblastic progenitor cells of
the perichondral mesenchyme (French et al., 2004). The ABA
also does not reveal the presence of CCN4 mRNA during
development after E11.5 (Figure 2). But, both the ABA and BS*
suggest that CCN4 mRNA is present in the adult murine brain,
although at relatively low levels, with the highest expression
in the olfactory bulb (ABA, BS*) and retina (BS*; Figure 3).
Also, the HPA shows presence of CCN4 protein in the adult
human cerebral cortex and cerebellum (Figure 4), with the
highest expression levels in cortical endothelial cells and Purkinje
neurons (Table 3). Additionally, CCN4 protein was shown to
be expressed in rat primary neurons during oxygen-glucose
deprivation (Wang et al., 2012). CCN5 mRNA, according to the
ABA, is not present in P56 murine brain (Figure 3). But the
BS* reports low to moderate CCN5 mRNA levels throughout
the adult mouse CNS, with the highest expression in the retina.
Moreover, Ohkawa et al. (2011) detected some CCN5 mRNA
in the cerebellum and spinal cord of 15 week old mice. In
contrast, CCN5 immunostaining was reported in fetal mouse
brain (E12–16) but not human brain (4 months; Jones et al.,
2007). Cytoplasmic and nuclear CCN5 immunostaining was also
reported in cortical neurons in the adult rat (Gray et al., 2007).
The presence of CCN5 protein in the adult cortex is supported by
the HPA (Figure 4), which additionally provides evidence of its
hippocampal expression. Virtually nothing is known for CCN6.
No data are reported concerning its expression in either the ABA
or HPA. Only a BS* microarray analysis detected almost equal
amounts of CCN6 transcript in all 51 analyzed brain regions.
Role of CCN Proteins in the Central Nervous
System
CCNs can be detected in the CNS. Importantly, CCN levels
dynamically change during development. This observation
supports their possible role in CNS development and
physiological functions. Here, we will discuss the available
data that indicate the involvement of CCN proteins, mainly
CCN1, CCN2, and CCN3, in CNS development and physiology.
CCN1
In 1998, CCN1 was suggested to play an important role in
neuronal differentiation, in which it was induced by bFGF during
the differentiation of immortalized hippocampal progenitor
(H19–7) cells (Chung and Ahn, 1998). Indeed, we recently
confirmed that CCN1 is required for proper development of
the dendritic tree in rat hippocampal neurons in vitro and
acts downstream of Ras, ERK, and PI3K. Moreover, CCN1
overexpression promoted dendritic branching, and this effect
depended on β1-integrin (Malik et al., 2013).
CCN1 is secreted by retinal Muller glial (RMG) cells
that are cultured in vitro in response to glial cell line-
derived neurotrophic factor (GDNF) treatment, which is
known to have pro-survival effects in the retina. Thus, the
neuroprotective and pro-survival activity of CCN1 was studied
in a mouse model of retinitis pigmentosa (Kucharska et al.,
2014). In organotypic retinal cultures that were derived from
these mice, CCN1 treatment increased the survival rates of
photoreceptors. The authors showed that CCN1 activates
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the mitogen-activated protein kinase (MAPK)/Erk and Janus-
associated kinase (JAK)/Stat pathways but not PI3K/Akt
pathway in retinal explants from retinitis pigmentosa mice.
Interestingly, in primary porcine cultures, CCN1 did not
stimulate photoreceptors themselves but rather only RMG
cells and retinal pigment epithelium (RPE) cells, suggesting
that the protective effect on photoreceptors occurs indirectly.
In disagreement with the results that were obtained in the
retinitis pigmentosa model, CCN1 treatment in pure porcine
RMG cultures stimulated not only the MAPK/Erk and JAK/Stat
pathways but also the PI3K/Akt pathway, whereas it led to
activation of the PI3K/Akt and MAPK/Erk pathways in RPE
cultures.
The stimulation of muscarinic acetylcholine receptors
(mAChRs) induced CCN1 mRNA expression in primary
neurons and the rat brain, in which CCN1 mRNA was detected
in cortical layers V and VI and thalamic nuclei. mAChRs
modulate neuronal functions, including long-term potentiation
and synaptic plasticity in neuronal circuits that are involved in
learning and memory formation. The authors suggested a role
for CCN1 in the cholinergic regulation of synaptic plasticity
(Albrecht et al., 2000).
CCN2
Consistent with its expression pattern, CCN2 was shown to
play an important role in the rodent olfactory bulb, where it
acts as a proapoptotic factor that eliminates newborn neurons
in an activity-dependent and locally restricted manner. CCN2
acts via glial-derived transforming growth factor β2 (TGF-β2)
to promote the apoptosis of newly generated periglomerular
interneurons in the glomerular layer (Khodosevich et al., 2013).
CCN2 levels, which are dynamically regulated in response to
changes in olfactory input, adjust the survival of postnatally
born neurons in an odorant-specific fashion. Importantly, CCN2
levels decrease in the mouse olfactory bulb if the sensory input
is suppressed (Khodosevich et al., 2013). In contrast, olfactory
activity enhances CCN2 expression specifically in odor-activated
glomeruli in the olfactory bulb. This phenomenon has important
behavioral consequences, and CCN2 knockdown mice perform
better in odorant detection and olfactory discrimination than
controls.
As mentioned above, CCN2 binds TrkA and p75NTR,
receptors that transduce neurotrophin signals (Wahab et al.,
2005). The authors showed that CCN2 stimulates TrkA and
induces its autophosphorylation. The nerve growth factor
(NGF)-induced activation of TrkA is widely known to control
neuronal cell survival and axonal growth (Kuruvilla et al., 2000;
Atwal et al., 2003). Nonetheless, the physiological importance
of CCN2’s influence on neurotrophin signaling in brain
development, physiology, and disease remains to be evaluated.
CCN3
A role for CCN3 in brain development has also been reported.
Specific patterns and dynamic changes inCCN3 expression in the
rat cerebellum (Le Dréau et al., 2010b) likely reflect its function
in postnatal cerebellum development. Supporting this possibility,
an in vitro study showed that CCN3 reduces cerebellar granule
neuron precursor (GNP) proliferation that is induced by Sonic
Hedgehog (SHH). SHH maintains GNPs in a proliferative
state and delays their differentiation, resulting in a decrease
in the proportion of postmitotic neurons. By counteracting
SHH-driven effects, CCN3 reduces the proliferation of GNPs
and consequently promotes their differentiation. This anti-
proliferative action of CCN3 requires glycogen synthase kinase
3β (GSK3-β) activity. Moreover, CCN3 stimulates the migration
and chemotaxis of cerebellar GNPs in vitro (Le Dréau et al.,
2010b). The role of CCN3 in the retina has also been studied.
CCN3 is expressed in the chick retina during development in
distinct cell types and is regulated by the Notch and BMP
signaling pathways (Laurent et al., 2012). However, the ectopic
expression of CCN3 had no effect on retinal development. These
authors did not describe the effects of CCN3 depletion, and the
possible role of CCN3 in the developing retina remains unclear
(Laurent et al., 2012).
CCN5
A role for CCN5 in neuronal development has also been
suggested. CCN5 was shown to enhance neurite outgrowth
in Neuro2a cells. The underlying mechanism remains elusive,
although the authors suggested the involvement of the CCN5-
triggered, β1-integrin-dependent activation of Akt (Ohkawa
et al., 2011). Thus, far no data are available concerning neuronal
functions of CCN4 and CCN6. Most likely almost complete lack
of data concerning role of CCN4, 5 and 6 in the nervous system
reflects their low abundance in the nervous system and relatively
poor repertoire of tools to reliably study their expression.
Alternatively, those proteins may attract less attention when
identified in large ‘‘omics’’ screens because of limited knowledge
concerning their cellular functions.
CNN Proteins and Nervous System
Dysfunction
As in non-neuronal tissues, CCN proteins play a role in responses
to injury in the CNS. This role has been particularly attributed
to CCN2. CCN2 appears to be involved in gliosis and glia scar
formation in response to different types of brain injury, such as
trauma, cerebral infarction, and excitotoxic brain damage. After
kainic acid-induced lesions of the CA3 area of the hippocampus
(i.e., a model of excitotoxic brain damage), CCN2 protein was
detected in the CA1, CA3, and dentate gyrus, mainly in neurons
that mostly died on subsequent days. At later stages when repair
processes are active, CCN2 was found extracellularly and in
GFAP-positive astrocytes (Hertel et al., 2000).
CCN2 upregulation has also been observed in reactive gliosis
adjacent to the site of mechanical injury and in brain tissue in
stroke patients and following traumatic brain injury (Schwab
et al., 2000, 2001). A role in neuroinflammation has also been
suggested for CCN3. CCN3 protein was shown to be expressed
in astrocytes and regulate astrocyte chemokine synthesis in vitro
and in vivo (Le Dréau et al., 2010a). CCN3 was suggested to
attenuate inflammatory pain (Kular et al., 2012). CCN3 protein
expression decreased in dorsal root ganglia and the dorsal horn of
the spinal cord in a rat model of inflammatory pain. Interestingly,
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intrathecal administration of CCN3 siRNA during early stages of
an inflammatory pain model resulted in a significant increase in
mechanical allodynia. In contrast, CCN3 treatment significantly
attenuated mechanical allodynia in rats but had no effect on
basal pain perception in control animals. As demonstrated both
in vitro and in vivo, CCN3 influences matrix metalloproteinase
(MMP) expression, which might contribute to the possible
mechanism of CCN3’s involvement in inflammatory pain (Kular
et al., 2012).
The role of several CCN proteins has been suggested in
neurodegenerative disease, based largely on the observation
that they are expressed in patients’ brains in both neurons
and astrocytes. Notably, however, a causal role for CCN
proteins in neurodegeneration has not yet been proven, and
increased levels of CCNs might result from inflammation
that accompanies neurodegeneration. CCN2 appears to be
involved in the progression and persistence of astrogliosis
in neurodegenerative diseases, including amyotrophic lateral
sclerosis (ALS) and Alzheimer’s disease (AD). In AD patients’
brains, CCN2 protein was detected in the entorhinal cortex,
hippocampus, and temporal cortex, and the signal was associated
with neurofibrillary tangles and neurons that are associated
with amyloid plaques (Ueberham et al., 2003). Moreover,
CCN2 was detected in perivascular astrocytes and astrocytes
that were associated with plaques (Ueberham et al., 2003).
Another study showed that CCN2 expression in the AD brain
is correlated with the progression of clinical dementia in AD
and amyloid plaques but not neurofibrillary tangle pathology.
The authors suggested that CCN2 may play a role in the
pathogenesis of AD by promoting amyloid β peptide levels.
This hypothesis was supported by findings from a Tg2576
AD model in mice that were exposed to a diabetogenic
diet. These mice developed insulin resistance, accompanied by
elevations in CCN2 levels in the brain and the promotion
of AD-type amyloid plaque burden (Zhao et al., 2005). The
authors also found that CCN2 activated the MAPK and
PI3K/Akt pathways in human H4-APP751 neuronal cells and
suggested that this may lead to an increase in amyloid β
peptide levels and contribute to AD pathology (Zhao et al.,
2005).
CCN2 expression was also linked to ALS. In normal human
spinal cord, the low expression of CCN2 protein is observed in
cells with astroglial morphology, particularly in white matter.
CCN2 protein levels are increased in ALS cases. It can be detected
in vimentin-positive reactive astrocytes and remaining motor
neurons in the ventral horn in long-term-surviving patients
(Spliet et al., 2003).
CCN4 has been linked to neurodegeneration protection.
Treatment with CCN4 blocked primary neuronal injury and
apoptosis during oxygen-glucose deprivation, and this effect
depended on PI3K-Akt signaling (Wang et al., 2012).
Conclusions and Perspectives
CCN proteins have not been studied vigorously or systematically
in the nervous system, but their known functions in other
tissues and organs support their potential involvement in the
proper development and physiology of the nervous system.
Such a role is also supported by a few discoveries of CCNs’
involvement in neuroprecursors proliferation, neuronal survival,
and differentiation. Examples of nervous system pathologies
that are linked to changes in CCN gene expression support the
importance of CCNs in the nervous system. Yet, based on these
few examples it would be premature to build a comprehensive
model of CCN protein-dependent regulation of the nervous
system development and physiology. As in case of other systems,
it is very likely that the final outcome of CCN activities may
depend on cell type and repertoire of receptors expressed by
a given cell at a particular developmental/differentiation stage.
What is more, similar to studies on skeletal development,
studies in the context of the whole organism are key to
understanding CCNs’ modulatory functions. Therefore, further
progress in our understanding of the functions of CCNs in
the nervous system will require the development of animal
models using spatially and developmentally regulated knockouts
of CCN family genes. Studies on the role of CCNs in the
nervous system can accelerate in the future only with such
models.
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